BNT211 is an autologous CAR T-cell therapy that targets oncofetal antigen claudin 6 (CLDN6), according to the company. BNT211 is currently in trials for assessment as a monotherapy, as well as in combination with a CLDN6 mRNA-based vaccine (CARVac), for the treatment of relapsed or refractory advanced solid tumors, BioNTech said.

Pfizer-BioNTech COVID-19 vaccine safe for kids ages 5-11
Pfizer and BioNTech's COVID-19 vaccine is safe and well tolerated and showed robust neutralizing antibody responses in children between the ages of 5...

BioNTech takes over U.S. Kite cell therapy manufacturing site
BioNTech has completed the acquisition of a solid tumor neoantigen T-cell receptor R&D platform and clinical manufacturing facility from Kite, a Gilead...

Africa to get doses of Pfizer-BioNTech COVID-19 vaccine
Pfizer and BioNTech have signed a letter of intent with South Africa-based Biovac Institute to manufacture and distribute the companies' COVID-19 vaccine...

U.S. to donate 500M doses of Pfizer-BioNTech COVID-19 vaccines
The U.S. government is buying 500 million doses of the Pfizer-BioNTech COVID-19 vaccine to distribute to low- and lower middle-income countries and...

FDA authorizes Pfizer-BioNTech COVID-19 vaccine for adolescents
The U.S. Food and Drug Administration (FDA) expanded the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine to include adolescents...